Diffuse intrinsic pontine glioma
A diffuse intrinsic pontine glioma is a tumour located in the pons of the brain stem. Glioma is a general name for any tumour that arises from the supportive tissue called glia, which help keep the neurons in place and functioning well. DIPG is a brainstem glioma. The brain stem is the bottommost portion of the brain, connecting the cerebrum with the spinal cord. The majority of brain stem tumours occur in the pons and are diffusely infiltrating, and therefore cannot be surgically removed. The brain stem contains all of the incoming neurons within the spinal cord, as well as important structures involved in eye movements and in face and throat muscle control and sensation.
Diagnosis
Like for most brainstem tumors, diagnosing diffuse intrinsic pontine glioma usually involves non-invasive brain imaging like MRI, in addition to neurologic physical exam. Biopsies and other procedures are very uncommon. Similar to DIPG, diffuse midline gliomas often fall into similar categories for both diagnosis and treatment as DIPG and are often categorized together. More recently, biopsies are performed so that the best option for clinical trials can be chosen.In studies resulting from the DIPG/DMG Registry and in connection with the DIPG/DMG Collaborative, statistics reveal that approximately 150-300 patients are diagnosed with DIPG in the USA per year, the median age of patients with DIPG is approximately 6–7 years old and the male/female ratio of DIPG patients is 1:1.
Treatment
The standard treatment for DIPG is 6 weeks of radiation therapy, which often dramatically improves symptoms. However, symptoms usually recur after 6 to 9 months and progress rapidly.Neurosurgery
Surgery to attempt tumour removal is usually not possible or advisable for DIPG. By nature, these tumors invade diffusely throughout the brain stem, growing between normal nerve cells. Aggressive surgery would cause severe damage to neural structures vital for arm and leg movement, eye movement, swallowing, breathing, and even consciousness.A neurosurgically performed brain-stem biopsy for immunotyping of diffuse intrinsic pontine glioma has served a limited recent role in experimental clinical studies and treatment trials. This, however, is not the current standard of care, as it presents considerable risk given the biopsy location, and thus is appropriately performed only in the context of participation in an ongoing clinical treatment trial.
Pontine biopsy is in no way a therapeutic or curative surgery, and the risks are only outweighed when the diagnosis is uncertain or the patient is enrolled in an approved clinical trial.
Radiotherapy
Conventional radiotherapy, limited to the involved area of tumour, is the mainstay of treatment for DIPG. A total radiation dosage ranging from 5400 to 6000 cGy, administered in daily fractions of 150 to 200 cGy over 6 weeks, is standard. Hyperfractionated radiotherapy was used previously to deliver higher radiation dosages, but did not lead to improved survival. Radiosurgery has a role in the treatment of DIPG and may be considered in selected cases.Chemotherapy and other drug therapies
The role of chemotherapy in DIPG remains unclear. Studies have shown little improvement in survival, although efforts through the Children's Oncology Group, Paediatric Brain Tumour Consortium, and others are underway to explore further the use of chemotherapy and other drugs. Drugs that increase the effect of radiotherapy have shown no added benefit, but promising new agents are under investigation. Immunotherapy with beta-interferon and other drugs has also had little effect in trials. Intensive or high-dose chemotherapy with autologous bone marrow transplantation or peripheral blood stem cell rescue has not demonstrated any effectiveness in brain stem gliomas. Future clinical trials may involve medicines designed to interfere with cellular pathways, or other approaches that alter the tumor or its environment.Prognosis
DIPG has a 5-year survival rate of <1%. The median overall survival of children diagnosed with DIPG is approximately 9 months. The 1- and 2-year survival rates are approximately 30% and less than 10%, respectively. These statistics make DIPG one of the most devastating pediatric cancers. Although 75–85% of patients show some improvement in their symptoms after radiation therapy, DIPGs almost always begin to grow again. Clinical trials have reported that the median time between radiation therapy and progression is 5–8.8 months. Patients whose tumors begin to grow again may be eligible for experimental treatment through clinical trials to try to slow or stop the growth of the tumor. However, clinical trials have not shown any significant benefit from experimental DIPG therapies so far.DIPGs that progress usually grow quickly and affect important parts of the brain. The median time from tumor progression to death is usually very short, between 1 and 4.5 months. During this time, doctors focus on palliative care: controlling symptoms and making the patient as comfortable as possible.
Research
As is the case with most brain tumors, a major difficulty in treating DIPG is overcoming the blood–brain barrier.In the brain – unlike in other areas of the body, where substances can pass freely from the blood into the tissue – there is very little space between the cells lining the blood vessels. Thus, the movement of substances into the brain is significantly limited. This barrier is formed by the lining cells of the vessels as well as by projections from nearby astrocytes. These two types of cells are knitted together by proteins to form what are called "tight junctions". The entire structure is called the blood–brain barrier. It prevents chemicals, toxins, bacteria, and other substances from getting into the brain, and thus serves a continuous protective function. However, with diseases such as brain tumors, the BBB can also prevent diagnostic and therapeutic agents from reaching their target.
Researchers and clinicians have tried several methods to overcome the blood–brain barrier:
- Intrathecal/intraventricular administration: Chemotherapy is injected directly into the cerebrospinal fluid, either through a lumbar puncture or a surgically implanted catheter.
- Intracerebral implants: A neurosurgeon creates a cavity within a tumor to allow the placement of dime-sized chemotherapy wafers, such as Gliadel wafers. Several of these wafers can be placed at the time of surgery and will release the chemotherapy agent carmustine slowly over time. This provides a much higher concentration of chemotherapy in the brain than can be obtained with intravenous administration, and it causes fewer systemic side effects. However, it is an option only for patients with surgically resectable tumours; it cannot be used to treat DIPG.
- Osmotic blood–brain barrier disruption : The cells of the blood–brain barrier are shrunk by a concentrated sugar solution. This opens the barrier and allows 10 to 100 times more chemotherapy to enter the brain. A catheter is placed into a large artery and threaded up to the carotid or vertebral artery. The hypertonic mannitol is injected, followed by a chemotherapeutic agent. Patients spend a few days in the hospital for each administration. This has been attempted with DIPG tumours.
- Convection-enhanced delivery: Chemotherapy is delivered to the tumour by a surgically implanted catheter under a pressure gradient to achieve more distribution than with diffusion alone. Limited experiments have been conducted with brain tumors, including one with a DIPG.
- Drug carriers: Carriers such as "Trojan horse" molecules, liposomes, and nanoparticles might theoretically allow a therapeutic drug to enter the brain. Such tactics are mostly in the investigatory stages and are not yet clinically relevant to brain tumour treatment.
Starting in 2011 at the DIPG Symposium, under the cooperation of the DIPG Collaborative , The Cure Starts Now Foundation and 114 hospitals from 15 countries around the world, the International DIPG/DMG Registry was established creating the first linked platform of data collection for this disease. As of March, 2020, over 1100 patients and families have contributed to this database making it the largest genomic, tissue, demographic and radiological database for DIPG and DMG in the world.
In 2019, The Cure Starts Now Foundation and the DIPG Collaborative partnered with the International DIPG Registry to develop as a source of all current DIPG and DMG data, developed from current studies and expert articles by leading professionals.
Prominent patients
, a DIPG patient from Lawrenceburg, Indiana, made national news headlines in the United States for her performance in high school basketball, followed by college basketball at Mount St. Joseph University near Cincinnati. Shortly before she was incapacitated by the tumour, MSJ and Hiram College held a sold-out game for her at Xavier University's Cintas Center. NBA star LeBron James posted words of encouragement on Instagram, and Pat Summitt and the Indiana Pacers gave $5,000 to Hill's charity. Doctors said she could become the "face" of DIPG, much in the same way that Lou Gehrig was the public face of Amyotrophic lateral sclerosis. Hill said she "didn't want to be another local story that disappeared and just became another statistic on a paper", and that she would "do anything she could to be the voice for little kids". She died on April 10, 2015. Ultimately her efforts raised nearly $2.5 million for new research and formed The Cure Starts Now chapter in her honor.Elena Desserich, from the Cincinnati suburb of Wyoming, Ohio, United States, was the subject of the book Notes Left Behind, originally self-published in 2009. It soon received national attention and was later re-published in 2009 by HarperCollins Publishers. It was listed as a New York Times Best Seller shortly thereafter. It was later reprinted in 22 different languages worldwide. Diagnosed with DIPG in 2006, her parents were told she had just 275 days to live. Her parents vowed to make what remained of Elena's life as special as possible. She lived for 10 months after her diagnosis, eventually being paralysed and left unable to speak by the cancer. She died in August 2007. Shortly after, her parents and younger sister began finding notes all over the house. Her parents didn't tell Elena her prognosis, but retrospectively believe that she knew it. The book also contains entries from Elena's parents' diary as well as several of Elena's drawings. The Cure Starts Now Foundation was founded after her passing and from the proceeds of the book. As of 2020, The Cure Starts Now Foundation had over 40 chapter locations in 3 countries and was a leading funder of over $14 million in DIPG/DMG research in 15 countries and over 90 trials.
Nathaniel "Kayne" Finley, an 18 year old from Florida, was diagnosed with DIPG in November 2016. After a year long battle and striving to live life to its fullest, Kayne passed away in November 2017. His legacy, "Cannonballs for Kayne" the non profit organization that he founded is now run by his family who cherish his memory and continue raising awareness for DIPG in his stead.
Emma Mertens, an 8-year-old from Hartland, Wisconsin, was diagnosed with DIPG in January 2019 and died in November. Mertens, a dog lover, received over 80,000 emails and letters of dog photos after her case went viral. A foundation launched by her and her parents donated more than 3,000 stuffed animals and 1,000 books.
In June 1961, Karen Armstrong, daughter of Neil Armstrong and Janet Elizabeth Shearon, was diagnosed with a diffuse intrinsic pontine glioma. X-ray treatment slowed its growth, but her health deteriorated to the point where she could no longer walk or talk. She died of pneumonia, related to her weakened health, on January 28, 1962, aged two.
Stevie Lynn Stock, the daughter of blogger and Instagram personality Ashley Stock, was diagnosed with DIPG in April 2020. She passed away six weeks later at age 3 on May 27, 2020, after being taken to hospital due to her rapidly declining motor function.